Retreatment of chronic hepatitis c infection with telaprevir: Preliminary results in Turkey

Basit Öğe Kaydı
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorYıldız, Orhan
dc.contributor.authorAkhan, Sıla
dc.contributor.authorÇelen, Mustafa Kemal
dc.contributor.authorUral, Onur
dc.contributor.authorKoruk, Süda Tekin
dc.contributor.authorKöse, Şukran
dc.contributor.authorKorkmaz, Fatime
dc.contributor.authorKuruüzüm, Ziya
dc.contributor.authorTuna, Nazan
dc.contributor.authorTaheri, Serpil
dc.contributor.authorSayan, Murat
dc.contributor.authorDemir, Nazlım Aktuğ
dc.contributor.authorSümer, Şua
dc.contributor.authorAltınok, Elif Sargın
dc.date.accessioned2020-03-26T19:06:57Z
dc.date.available2020-03-26T19:06:57Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: The use of pegylated interferon alpha and ribavirin (PegIFN/RBV) for the retreatment of chronic hepatitis C virus (HCV) infection without a sustained virological response (SVR) prior to PegIFN/RBV treatment has resulted in low success rates. Aims: To investigate the efficacy and safety of telaprevir (TVR) in combination with PegIFN/RBV in patients infected with HCV genotypes 1 and 4 who were previously treated with PegIFN/RBV and failed to achieve SVR. Study Design: Multi-center, retrospective, cross-sectional study. Methods: The study included 111 patients: 80 prior relapsers, 25 prior null responders, and six prior partial responders to PegIFN/RBV treatment. The patients were given TVR/PegIFN/RBV for 12 weeks, followed by a 12-week PegIFN/RBV treatment; virological response results were assessed at weeks 4, 12, and 24. Treatment was discontinued in patients with HCV RNA >1000 IU/mL at week 4 or with negative RNA results at week 4 but >1000 IU/mL at week 12. Rapid virological response (RVR), early virological response (EVR), extended rapid virological response (eRVR), and virological response at 24th week of treatment were evaluated. The side effects of combination therapy and the rates of treatment discontinuation were investigated. Results: The mean age of the patients was 56.02 +/- 9.96 years and 45.9% were male. Ninety-one percent of the patients were infected with viral genotype 1, 69.6% with the interleukin (IL) 28B genotype CT and 20.2% were cirrhotic. The RVR rate was 86.3% in prior relapsers, 56% in prior null responders, and 50% in prior partial responders (p=0.002). EVR rates in those groups were 91.3%, 56%, and 83.3%, respectively (p<0.001). eRVR rates were 83.8% in prior relapsers, 48% in prior null responders, and 50% in prior partial responders (<0.001). The virological response at the 24th week of treatment was found to be the highest in prior relapsers (88.8%); it was 56% in prior null responders and 66.7% in prior partial responders (p<0.001). Common side effects were fatigue, headache, anorexia, malaise, anemia, pruritus, dry skin, rash, dyspepsia, nausea, pyrexia, stomachache, and anorectal discomfort. All treatments were discontinued due to side effects in 9.9% of patients. Conclusion: High virological response rates were obtained with TVR/PegIFN/RBV treatment. Although side effects were frequently observed, the discontinuation rate of combination therapy was low.en_US
dc.identifier.citationAygen, B., Yıldız, O., Akhan, S., Çelen, M. K., Ural, O., Koruk, S. T., Köse, Ş., Korkmaz, F., Kuruüzüm, Z., Tuna, N., Taheri, S., Sayan, M., Demir, N. A., Sümer, Ş., Altınok, E. S. (2015). Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey. Balkan Medical Journal, 32(3), 266-277.
dc.identifier.doi10.5152/balkanmedj.2015.15366en_US
dc.identifier.endpage272en_US
dc.identifier.issn2146-3123en_US
dc.identifier.issn2146-3131en_US
dc.identifier.issue3en_US
dc.identifier.pmid26185714en_US
dc.identifier.startpage266en_US
dc.identifier.urihttps://dx.doi.org/10.5152/balkanmedj.2015.15366
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32517
dc.identifier.volume32en_US
dc.identifier.wosWOS:000357330600005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUral, Onur
dc.institutionauthorDemir, Nazlım Aktuğ
dc.institutionauthorSümer, Şua
dc.language.isoenen_US
dc.publisherGALENOS YAYINCILIKen_US
dc.relation.ispartofBalkan Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectChronic hepatitis Cen_US
dc.subjecttelapreviren_US
dc.subjecttherapyen_US
dc.subjecttreatment-experienceden_US
dc.titleRetreatment of chronic hepatitis c infection with telaprevir: Preliminary results in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bilgehan AYGEN.pdf
Boyut:
262.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji /Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu